Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00781287 · ClinicalTrials.gov registry record · Phase 4
Raltegravir (Isentress/MK-0518) and HIV-1 Infected CD4 Cells During Acute/Early HIV-1
A Phase 4 study, sponsored by University of Washington.
- Terminated
- Registry status
- Phase 4
- Development phase
- 10
- Enrollment target
NCT00781287 is a Phase 4 study that was terminated before completion, run by University of Washington. The registered enrollment target is 10 participants.
The verdict
NCT00781287, a Phase 4 study, was terminated before completion, sponsored by University of Washington.
- TERMINATED
- Registry status
- Phase 4
- Development phase
- 10 participants
- Enrollment target
Study Summary
This is an investigator-initiated, two-year, randomized, controlled, single-center, open-label, pilot study comparing 3-drug highly active antiretroviral therapy (HAART) to 3-drug HAART plus raltegravir for persons with acute and early HIV-1 infection. The study will test the hypothesis that use of the integrase inhibitor raltegravir (400 mg BID orally) to inhibit the integration step of the HIV-1 life cycle in conjunction with HAART in subjects with recently acquired HIV-1 infection will decrease the number of HIV-1 infected CD4+ T-cells to a greater extent than a 3-drug HAART regimen.
Interventions
- DRUG Raltegravir
- DRUG 3-drug anti-HIV therapy
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 10 participants |
| Start Date | 2009-02 |
| Est. Completion | 2013-10 |
| Phase | Phase 4 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00781287
The ClinicalTrials.gov registry entry for NCT00781287 describes a study currently listed as terminated, categorized as Phase 4. The registered enrollment target is 10 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is University of Washington, which has 1,048 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 2 interventions - of which Raltegravir is the first listed.
NCT00781287 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT00781287 about?
NCT00781287 is a clinical study titled "Raltegravir (Isentress/MK-0518) and HIV-1 Infected CD4 Cells During Acute/Early HIV-1". This is an investigator-initiated, two-year, randomized, controlled, single-center, open-label, pilot study comparing 3-drug highly active antiretroviral therapy (HAART) to 3-drug HAART plus raltegravir for persons with acute and early HIV-1 infection. The study will test the hypothesis that use of ...
What is the current status of trial NCT00781287?
This trial is currently terminated. It is a Phase 4 study. The enrollment target is 10 participants. The study started on 2009-02. Estimated completion is 2013-10.
What interventions are being tested in trial NCT00781287?
The interventions under investigation include: Raltegravir (DRUG), 3-drug anti-HIV therapy (DRUG).
Who is sponsoring clinical trial NCT00781287?
This trial is sponsored by University of Washington, which has 1,048 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.